HomeSGX-LISTED COMPANIESGreat Eastern's Strong 1H-25 Financial Results

Great Eastern’s Strong 1H-25 Financial Results

Published on

spot_img

Great Eastern Holdings’ 1H-25 financial results show modest growth in profit attributable to shareholders, propelled by robust investment performance and a growing underlying insurance business. Despite a decline in total weighted new sales, new business embedded value saw strong growth due to an improved sales mix. An interim dividend was also declared, and a bonus issue is proceeding.

• Discover how strategic shifts in product offerings led to enhanced long-term profitability, even amidst a decline in sales volume
• Uncover the key financial drivers behind the company’s increased returns for shareholders
• Learn about Great Eastern’s commitment to progressive dividends and its investments in future growth initiatives

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...